slide1.jpg

NEWS!

We have developed
blood cells, cMylc, for
research of COVID-19!

We have developed a human white blood cells, cMylc, based on Mylc cell optimized for the evaluation of the efficacy and safety of vaccines and drugs for COVID-19, which is shaking the world!
High precision and uniform blood cells produced using regenerative medicine technologies drastically accelerate the evaluation of the efficacy of drugs for COVID-19.
(Please contact us for details.)

We are providing high precision immature blood cells developed for various types of evaluation of drugs and functional materials for cosmetics and foods, and offer a contract evaluation service using the blood cells.

PRODUCTS

High precision artificial blood cells

We can provide various types of uniform and high precision blood cells with identical genetic background, in any quantity you need, using iPS cell technology (regenerative medicine technology).

More information on the products

SERVICE

Contract evaluation service

​

We also provide a contract evaluation service using our products for drugs and functional materials. You can select and design the blood cells. Our high precision and efficient evaluation can save you time and money.

More information on the evaluation services
Mylc changes
(artificial dendritic cells produced using regenerative medicine technology)
the future of development of drugs and functional materials and research of infectious diseases!

© 2020 MiCAN Technologies Inc.

615-8245  京都市西京区御陵大原1-36　京大桂ベンチャープラザ

KKVP, 1-36 Goryo-ohara, Nishikyo-ku, Kyoto 615-8245 Japan